Abstract:Introduction Accumulation of senescent cells is observed in various organs including vasculature, heart and white adipose tissue with age, and known to become a substrate of pathophysiology of various cardiovascular-metabolic diseases. We have previously developed a vaccine to eliminate senescent cells, so-called "senolytic vaccine" by targeting Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) as a cellular-senescence-associated cell surface protein. We have demonstrated that GPNMB senolytic vaccine could remove senescent cells and alleviate the pathology cardiovascular-metabolic diseases. Senescence-associated adhesion molecule 1 (SAAM-1) is also known as a cell-surface membrane to increase its expression during cellular senescence in endothelial cells as well as the development of cardiovascular diseases. Here, we identified SAAM-1 as another senescence antigen and created a vaccine to eliminate senescent cells by targeting SAAM-1. Purpose This study was purposed to evaluate the efficacy of SAAM-1 vaccine for the treatment of cardiovascular diseases in mice models. Methods As a pressure overload-induced heart failure (HF) model, C57BL/6N wild type (WT) mice were underwent transverse aortic constriction (TAC) or sham opretaion at 13 weeks of age. SAAM-1 or control vaccination were given at 8 and 10 weeks of age before operation. Echocardiography examination was conducted two weeks after TAC operation, followed by tissue sampling 3 weeks after the examination. As an atherosclerosis model, ApoE KO mice were subjected to a high-fat diet (HFD) starting at 4 weeks of age. Vaccination of ApoE KO mice was administered at 8 weeks of age with SAAM-1-vaccine or control-vaccine, followed by sacrifice 4 weeks later for further analysis. ApoE-KO mice were also crossed with p16-mediated Luciferase expressing mice (p16-Luc mice) and subjected to generation of atherosclerosis model. Results SAAM-1 expression was significantly increased in left ventricle (LV) in TAC mice but its increase was suppressed by SAAM-1 vaccination. Interestingly, both worsening systolic function and dilatation of LV by pressure overload were significantly alleviated by SAAM-1 vaccination. Furthermore, expression level of senescent markers including p16 and p21, as well as several inflammation markers were increased in failing heart along with development of cardiac fibrosis, but SAAM-1 vaccine could significantly attenuate this pathological change. In ApoE KO mice, SAAM-1 vaccine decreased expression level of several inflammation markers in the mice, along with a decreasing p16 signal in the aorta. Conclusions Targeting SAAM-1 for vaccination would be a novel and promising approach to alleviating age-related cardiovascular disease.

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

In Vivo Targeted Delivery of ANGPTL8 Gene for Beta Cell Regeneration in Rats

COL6A6 Peptide Vaccine Alleviates Atherosclerosis through Inducing Immune Response and Regulating Lipid Metabolism in Apoe−/− Mice

New Insights into ANGPLT3 in Controlling Lipoprotein Metabolism and Risk of Cardiovascular Diseases

Targeting angiopoietin-like 3 (ANGPTL3) in atherosclerosis: from bench to bedside.

Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside

Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia

A Novel Fully Human Anti-Nt-angptl3 Antibody from Phage Display Library Exhibits Potent ApoB, TG, and LDL-C Lowering Activities in Hyperlipidemia Mice.

VACCINATION AGAINST AGE-LDL SIGNIFICANT ATTENUATES ATHEROSCLEROSIS IN DIABETIC APOE MICE

A Novel Nanobody-Heavy Chain Antibody Against Angiopoietin-Like Protein 3 Reduces Plasma Lipids and Relieves Nonalcoholic Fatty Liver Disease

Modulation of Recombinant Antigenic Constructs Containing Multi-Epitopes Towards Effective Reduction of Atherosclerotic Lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J Mice.

ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients

Vaccine Targeting Alpha 1D-Adrenergic Receptor Improved Metabolic Syndrome in Mice

Downregulation of G3BP2 Reduces Atherosclerotic Lesions in ApoE Mice

Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice

Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects

Vaccination targeting senescence-associated transmembrane protein alleviated cardiovascular pathology in the mice

ANGPTL3 accelerates atherosclerotic progression via direct regulation of M1 macrophage activation in plaque

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk

Targeting ANGPTL3 by GalNAc-conjugated Sirna ANGsiR10 Lowers Blood Lipids with Long-Lasting and Potent Efficacy in Mice and Monkeys.